stockrow
Friday 6 November 2026
Export CNXU’s income statement to Excel — free account
Conexeu Sciences Inc.
CNXU Healthcare Biotechnology
- EPS
- −214.9%
- Free cash flow
- −1,084.3%
Quarter to July 2026, against a year earlier
2.09
0.13
−5.86%
Follow CNXU
Alert me
| Oct '24 | Oct '25 | |
|---|---|---|
Current Ratio |
1.02 | 22.20 |
Net Debt/EBITDA |
0.49 | 1.23 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.48 | 0.43 |
Capex/Depreciation |
— | (1.08) |
Interest Coverage |
(39.02) | (808.65) |
| 0.00% | (105.36%) | |
| 0.00% | (95.43%) | |
ROIC |
0.00% | (98.33%) |
Return on Tangible Assets |
(7,490.48%) | (55.00%) |
Average Days of Receivables |
— | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.35 | 0.02 |
Free Cash Flow per Share |
(0.03) | (0.13) |
Cash per Share |
0.05 | 0.38 |
Shareholders Equity per Share |
0.01 | 0.58 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.01 | 0.58 |
Free Cash Flow |
(0.23) | (1.69) |
Working Capital |
0.01 | 7.12 |
Capital Expenditures |
— | (0.02) |
Net Current Asset Value |
(0.09) | 7.12 |
| Other line items | ||
Quick Ratio |
0.92 | 20.35 |
Depreciation/Fixed assets |
— | 1.54 |
Cash ROIC |
(55.03%) | (13.86%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.03) | (0.13) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
— | 0.29 |
Average Assets |
— | 4.11 |
Average Common Equity |
— | 3.72 |
Capex to Sales |
— | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026